ICD-10 Coding for Abnormal PSA(N40.1, R97.20, R97.20B)
Learn about ICD-10 coding for abnormal PSA, including codes R97.20 and R97.21, documentation requirements, and common pitfalls.
Complete code families applicable to Abnormal PSA
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| R97.20 | Elevated prostate specific antigen [PSA] | Use for elevated PSA levels when there is no confirmed diagnosis of prostate cancer or other specific conditions. |
|
| R97.21 | Rising PSA following treatment for malignant neoplasm of prostate | Use for rising PSA levels in patients with a history of prostate cancer treatment. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutAbnormal PSA
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Abnormal PSA.
Vague documentation of PSA elevation
Impact
Clinical: May lead to inappropriate follow-up or treatment., Regulatory: Potential for audit issues., Financial: Risk of claim denials.
Mitigation
Include specific PSA values, Document clinical context
Using R97.20 with G0103 for screening
Impact
Reimbursement: Incorrect coding can lead to claim denials., Compliance: Non-compliance with Medicare guidelines., Data Quality: Inaccurate data on screening vs. diagnostic PSA tests.
Mitigation
Use Z12.5 with G0103 for screening purposes.
PSA Screening vs. Diagnostic Coding
Impact
Incorrect coding of PSA tests as diagnostic when they are screening.
Mitigation
Educate staff on correct code usage and documentation requirements.